Spots Global Cancer Trial Database for hedgehog
Every month we try and update this database with for hedgehog cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | NCT02151864 | Hepatocellular ... Cirrhosis | LDE225 | 18 Years - | University of California, San Diego | |
| Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients | NCT02762084 | Basal Cell Nevu... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815 | Metastatic Panc... | Gemcitabine, na... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | NCT04308395 | Basal Cell Nevu... | Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | NCT00636610 | Metastatic Colo... | Vismodegib 150 ... Placebo to vism... Bevacizumab Modified FOLFOX FOLFIRI | 18 Years - | Genentech, Inc. | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) | NCT03703310 | Basal Cell Nevu... | Patidegib Topic... Patidegib Topic... | 18 Years - | PellePharm, Inc. | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma | NCT00833417 | Basal Cell Carc... | Vismodegib 150 ... | 18 Years - | Genentech, Inc. | |
| An East Asian Study of LDE225 | NCT01208831 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | NCT00636610 | Metastatic Colo... | Vismodegib 150 ... Placebo to vism... Bevacizumab Modified FOLFOX FOLFIRI | 18 Years - | Genentech, Inc. | |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | NCT04308395 | Basal Cell Nevu... | Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
